Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dive deep into rare lung Cancer's DNA and immune defenses

NCT ID NCT07207278

Knowledge-focused Sponsor: First People's Hospital of Hangzhou Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a rare type of lung cancer called signet ring cell carcinoma. Researchers will analyze tumor samples from 39 Chinese patients to find genetic changes and immune system patterns. They hope to discover new markers that could lead to better, more personalized treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tyrosine kinase inhibitors (alectinib or crizotinib)
What this could lead to
If successful, this could identify new biomarkers and immune profiles to guide personalized treatment for lung signet ring cell carcinoma.
What could go wrong
This is a very small, early-stage study (39 people) focused on understanding the disease, not testing a treatment. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 39 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll adults (≥18 years) with newly diagnosed, histopathologically confirmed lung signet ring cell carcinoma (LSRCC) who have not received prior systemic anticancer therapy. All cases must have formalin-fixed paraffin-embedded (FFPE) tissue samples available. Additional inclusion criteria include measurable disease per RECIST v1.1 on contrast-enhanced CT, ECOG performance status 0-2, and adequate organ function. Patients with concurrent malignancies, prior exposure to any ALK-targeted agent, or known contraindications to TKI therapy are excluded.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1.Histologically confirmed, previously untreated LSRCC; 2. Adequate FFPE tumor tissue and paired adjacent non-tumor tissue available; 3. Expected survival ≥ 12 weeks; 4. Patients (or their legal guardians) willing and able to provide written informed consent; 5.Availability of complete pathology and imaging data. Exclusion Criteria: 1\. Prior systemic anticancer therapy; 2. Secondary LSRCC (i.e., metastatic signet ring cell carcinoma originating from a non-lung primary site); 3. Concurrent other malignancies; 4. Incomplete pathology results, missing imaging data, or unreliable follow-up information; 5. Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Signet ring cell carcinoma of the lung are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung signet ring cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Signet ring cell carcinoma of the lung

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310006, China